Browsing Cancer Therapeutics by author "Harrington, Kevin"
Now showing items 1-9 of 9
-
Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models.
Burley, TA; Da Pieve, C; Martins, CD; Ciobota, DM; Allott, L; et al. (SOC NUCLEAR MEDICINE INC, 2019-03-01)In head and neck squamous cell cancer, the human epidermal growth factor receptor 1 (EGFR) is the dominant signaling molecule among all members of the family. So far, cetuximab is the only approved anti-EGFR monoclonal ... -
Combining Molecularly Targeted Agents: Is More Always Better?
Sundar, R; Valeri, N; Harrington, KJ; Yap, TA (AMER ASSOC CANCER RESEARCH, 2017-03-01)The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming ... -
HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
Martins, CD; Da Pieve, C; Burley, TA; Smith, R; Ciobota, DM; et al. (AMER ASSOC CANCER RESEARCH, 2018-04-15)Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). ... -
Immunomodulatory activity of IR700-labelled affibody targeting HER2.
Mączyńska, J; Da Pieve, C; Burley, TA; Raes, F; Shah, A; et al. (SPRINGERNATURE, 2020-10-20)There is an urgent need to develop therapeutic approaches that can increase the response rate to immuno-oncology agents. Photoimmunotherapy has recently been shown to generate anti-tumour immunological responses by releasing ... -
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Samson, A; Scott, KJ; Taggart, D; West, EJ; Wilson, E; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2018-01-03)Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined ... -
Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment.
Burley, TA; Mączyńska, J; Shah, A; Szopa, W; Harrington, KJ; et al. (WILEY, 2018-06-01)Glioblastomas (GBMs) are high-grade brain tumors, differentially driven by alterations (amplification, deletion or missense mutations) in the epidermal growth factor receptor (EGFR), that carry a poor prognosis of just ... -
Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.
Mansfield, DC; Kyula, JN; Rosenfelder, N; Chao-Chu, J; Kramer-Marek, G; et al. (NATURE PUBLISHING GROUP, 2016-04-01)Oncolytic strains of vaccinia virus are currently in clinical development with clear evidence of safety and promising signs of efficacy. Addition of therapeutic genes to the viral genome may increase the therapeutic efficacy ... -
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
Dillon, MT; Boylan, Z; Smith, D; Guevara, J; Mohammed, K; et al. (ELSEVIER IRELAND LTD, 2018-08-01)PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and ... -
Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy.
Mączyńska, J; Raes, F; Da Pieve, C; Turnock, S; Boult, JKR; et al. (BMC, 2022-01-21)BACKGROUND: Surgical resection followed by chemo-radiation postpones glioblastoma (GBM) progression and extends patient survival, but these tumours eventually recur. Multimodal treatment plans combining intraoperative ...